Last 7 days
-15.0%
Last 30 days
-31.9%
Last 90 days
-37.2%
Trailing 12 Months
-73.7%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 298.1B | 1.4B | -4.03% | 17.35% | -148.75 | 210.51 | 20.37% | -37.45% |
ABBV | 275.1B | 58.1B | 2.18% | 0.81% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 85.3B | 12.2B | 6.89% | 19.23% | 19.66 | 7.01 | -24.26% | -46.28% |
VRTX | 77.6B | 8.9B | 3.23% | 21.68% | 23.36 | 8.69 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -5.08% | 16.85% | -20.78 | 22.66 | 22.88% | -32.64% |
SRPT | 11.2B | 933.0M | 4.06% | 58.34% | -15.86 | 11.96 | 32.93% | -67.99% |
UTHR | 9.9B | 1.9B | -15.84% | 20.83% | 13.6 | 5.11 | 14.88% | 52.86% |
MID-CAP | ||||||||
RARE | 2.6B | 363.3M | -18.31% | -45.95% | -3.69 | 7.18 | 3.39% | -55.81% |
MRTX | 2.2B | 12.4M | -14.38% | -52.88% | -3.03 | 180.64 | - | -27.34% |
SMALL-CAP | ||||||||
OPK | 960.5M | 1.0B | 17.43% | -62.90% | -2.92 | 0.96 | -43.42% | -989.45% |
ANIK | 408.6M | 152.4M | -10.15% | 6.80% | -25.95 | 2.68 | 5.37% | -174.76% |
INO | 239.4M | 10.3M | -31.91% | -73.70% | -0.86 | 23.33 | 478.23% | 7.85% |
ATOS | 87.4M | - | -7.38% | -53.06% | -3.6 | - | - | -4.49% |
TTOO | 3.3M | 23.8M | -29.85% | -97.83% | -0.05 | 0.14 | -17.54% | -36.25% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -10.9% | 10,262,268 | 11,520,729 | 2,658,294 | 2,728,738 | 1,774,758 |
Operating Expenses | -15.3% | 277,835,788 | 328,112,421 | 343,446,096 | 321,999,134 | 302,992,677 |
S&GA Expenses | -0.1% | 90,185,285 | 90,282,976 | 91,615,112 | 55,824,617 | 53,752,353 |
R&D Expenses | -21.1% | 187,650,503 | 237,829,445 | 251,830,984 | 266,174,517 | 249,240,324 |
EBITDA | 16.1% | -272,698,900 | -324,994,644 | -347,390,313 | -321,119,402 | - |
EBITDA Margin | 5.8% | -26.57 | -28.21 | -216 | -191 | - |
Earnings Before Taxes | 15.9% | -277,652,852 | -330,137,293 | -352,522,438 | -326,165,085 | -303,224,323 |
EBT Margin | 5.6% | -27.06 | -28.66 | -219 | -194 | - |
Interest Expenses | -11.7% | 1,253,952 | 1,420,777 | 1,583,663 | 1,736,901 | 1,936,447 |
Net Income | 15.8% | -279,818,065 | -332,302,506 | -354,687,651 | -328,330,298 | -303,658,710 |
Net Income Margin | 5.5% | -27.27 | -28.84 | -221 | -196 | - |
Free Cahsflow | 0.9% | -217,184,574 | -219,214,254 | -198,321,425 | -225,743,381 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -11.1% | 349 | 392 | 459 | 446 | 496 |
Current Assets | -10.0% | 315 | 350 | 416 | 400 | 448 |
Cash Equivalents | 110.7% | 46.00 | 22.00 | 41.00 | 59.00 | 71.00 |
Net PPE | -50.4% | 8.00 | 16.00 | 16.00 | 17.00 | 17.00 |
Goodwill | 0% | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 |
Liabilities | 0.7% | 126 | 125 | 162 | 90.00 | 96.00 |
Current Liabilities | 2.1% | 97.00 | 95.00 | 131 | 59.00 | 66.00 |
Shareholder's Equity | -16.6% | 222 | 267 | 298 | 355 | 400 |
Retained Earnings | -3.8% | -1,487 | -1,433 | -1,395 | -1,300 | -1,209 |
Additional Paid-In Capital | 0.6% | 1,711 | 1,701 | 1,694 | 1,642 | 1,610 |
Shares Outstanding | 6.0% | 249 | 235 | 219 | 217 | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 0.7% | -216 | -217 | -196 | -224 | -215 |
Share Based Compensation | -8.9% | 23.00 | 25.00 | 27.00 | 24.00 | 26.00 |
Cashflow From Investing | 123.2% | 110 | 49.00 | 60.00 | 121 | -175 |
Cashflow From Financing | -33.3% | 82.00 | 123 | 119 | 79.00 | 211 |
100%
97.3%
86.9%
Y-axis is the maximum loss one would have experienced if Inovio Pharmaceuticals was unfortunately bought at previous high price.
-20.0%
-26%
-27.4%
-47.5%
FIve years rolling returns for Inovio Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -4,727 | 43,273 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | - | 1,000 | -% |
2023-03-03 | TIAA, FSB | unchanged | - | -2,617 | 22,383 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -90.97 | -1,635,660 | 145,345 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -14,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -99.63 | -15,945 | 55.00 | -% |
2023-02-17 | Compass Wealth Management LLC | new | - | 265 | 265 | -% |
2023-02-16 | American Trust | new | - | 43,159 | 43,159 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | added | 60.94 | 482 | 482 | -% |
2023-02-15 | Financial Advocates Investment Management | sold off | -100 | -628,000 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | state street corp | 12.61% | 31,472,352 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.83% | 17,042,500 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.3% | 23,284,119 | SC 13G/A | |
Apr 11, 2022 | state street corp | 10.49% | 23,267,928 | SC 13G/A | |
Feb 11, 2022 | state street corp | 6.32% | 13,300,430 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 8.7% | 18,244,914 | SC 13G/A | |
Feb 11, 2021 | nikko asset management americas, inc. | 0% | 0 | SC 13G/A | |
Feb 11, 2021 | wasatch advisors inc | - | 0 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 5.42% | 9,185,639 | SC 13G/A | |
Feb 10, 2021 | state street corp | 5.25% | 8,894,555 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 0.26 -72.92% | 0.26 -72.92% | 0.26 -72.92% | 0.26 -72.92% | 0.27 -71.88% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 10-K | Annual Report | |
Mar 01, 2023 | 8-K | Current Report | |
Mar 01, 2023 | POS AM | POS AM | |
Mar 01, 2023 | POSASR | POSASR | |
Feb 28, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-13 | Weiner David B. | sold | -6,707 | 1.15 | -5,833 | - |
2023-03-11 | Weiner David B. | acquired | - | - | 11,666 | - |
2023-03-11 | Humeau Laurent | acquired | - | - | 59,737 | chief scientific officer |
2023-03-11 | KIES PETER | acquired | - | - | 59,737 | cfo |
2023-03-11 | KIES PETER | sold (taxes) | -35,493 | 1.13 | -31,410 | cfo |
2023-03-11 | Shea Jacqueline Elizabeth | sold (taxes) | -29,357 | 1.13 | -25,980 | chief executive officer |
2023-03-11 | Humeau Laurent | sold (taxes) | -23,343 | 1.13 | -20,658 | chief scientific officer |
2023-03-11 | Shea Jacqueline Elizabeth | acquired | - | - | 59,737 | chief executive officer |
2023-02-27 | Weiner David B. | sold | -14,935 | 1.28 | -11,668 | - |
2023-02-26 | Humeau Laurent | sold (taxes) | -35,759 | 1.28 | -27,937 | chief scientific officer |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues [Abstract] | |||
Revenue from collaborative arrangements and other contracts, including affiliated entity | $ 10,262,268 | $ 1,774,758 | $ 7,411,220 |
Operating expenses: | |||
Research and development | 187,650,503 | 249,240,324 | 94,245,436 |
General and administrative | 90,185,285 | 53,752,353 | 37,247,828 |
Total operating expenses | 277,835,788 | 302,992,677 | 131,493,264 |
Loss from operations | (267,573,520) | (301,217,919) | (124,082,044) |
Other income (expense): | |||
Interest income | 4,782,030 | 3,363,080 | 3,311,846 |
Interest expense | (1,253,952) | (1,936,447) | (8,702,450) |
Change in fair value of derivative liability | 0 | 0 | (75,670,977) |
(Loss) gain on investment in affiliated entities | (1,899,654) | (553,570) | 36,556,658 |
Net unrealized (loss) gain on available-for-sale equity securities | (7,846,172) | (3,222,838) | 1,695,497 |
Other (expense) income, net | (3,861,584) | 343,371 | (704,896) |
Gain on deconsolidation of Geneos | 0 | 0 | 4,121,075 |
Net loss before share in net loss of Geneos | (277,652,852) | (303,224,323) | (162,890,304) |
Share in net loss of Geneos | (2,165,213) | (434,387) | (4,584,610) |
Net loss | (279,818,065) | (303,658,710) | (167,474,914) |
Net loss attributable to non-controlling interest | 0 | 0 | 1,063,757 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ (279,818,065) | $ (303,658,710) | $ (166,411,157) |
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders | |||
Basic (in dollars per share) | $ (1.17) | $ (1.45) | $ (1.07) |
Diluted (in dollars per share) | $ (1.17) | $ (1.45) | $ (1.07) |
Weighted average number of common shares outstanding | |||
Basic (in shares) | 238,622,188 | 208,829,801 | 155,126,857 |
Diluted (in shares) | 238,622,188 | 208,829,801 | 155,126,857 |
Convertible Bonds | |||
Other income (expense): | |||
Gain (loss) on extinguishment of convertible bonds and senior notes | $ 0 | $ 0 | $ (8,177,043) |
6.50% Convertible Senior Notes Due 2024 | |||
Other income (expense): | |||
Gain (loss) on extinguishment of convertible bonds and senior notes | $ 0 | $ 0 | $ 8,762,030 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 46,329,359 | $ 71,143,778 |
Short-term investments | 206,669,397 | 330,170,940 |
Accounts receivable | 1,701,726 | 5,466,850 |
Accounts receivable from affiliated entities | 10,036,490 | 2,565,194 |
Prepaid expenses and other current assets | 50,130,481 | 38,836,991 |
Prepaid expenses and other current assets from affiliated entities | 375,227 | 261,192 |
Total current assets | 315,242,680 | 448,444,945 |
Fixed assets, net | 7,727,997 | 17,453,206 |
Investments in affiliated entity | 2,007,142 | 3,906,796 |
Intangible assets, net | 2,129,861 | 2,626,355 |
Goodwill | 10,513,371 | 10,513,371 |
Operating lease right-of-use assets | 10,228,207 | 11,571,026 |
Other assets | 684,044 | 1,425,794 |
Total assets | 348,533,302 | 495,941,493 |
Current liabilities: | ||
Accounts payable and accrued expenses | 79,686,885 | 47,644,530 |
Accounts payable and accrued expenses due to affiliated entities | 1,220,439 | 548,032 |
Accrued clinical trial expenses | 10,594,073 | 10,326,266 |
Deferred revenue | 0 | 21,628 |
Operating lease liability | 2,803,973 | 2,603,956 |
Grant funding liability | 2,475,031 | 4,559,721 |
Grant funding liability from affiliated entities | 87,673 | 37,500 |
Total current liabilities | 96,868,074 | 65,741,633 |
Deferred revenue, net of current portion | 0 | 64,361 |
Operating lease liability, net of current portion | 12,655,586 | 15,459,559 |
Deferred tax liabilities | 32,046 | 32,046 |
Other liabilities | 0 | 14,826 |
Total liabilities | 126,170,546 | 96,272,072 |
Commitments and contingencies | ||
Inovio Pharmaceuticals, Inc. stockholders’ equity: | ||
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 | 0 | 0 |
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021 | 253,090 | 217,382 |
Additional paid-in capital | 1,710,656,191 | 1,609,589,797 |
Accumulated deficit | (1,487,847,784) | (1,209,855,522) |
Accumulated other comprehensive loss | (698,741) | (282,236) |
Total Inovio Pharmaceuticals, Inc. stockholders’ equity | 222,362,756 | 399,669,421 |
Total liabilities and stockholders’ equity | 348,533,302 | 495,941,493 |
6.50% Convertible Senior Notes Due 2024 | ||
Current liabilities: | ||
Convertible senior notes | $ 16,614,840 | $ 14,959,647 |